Physician profile
William Mckee
NPI 1205185477
$4,076.49
in general payments reported to CMS, 2019-2025
32 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $393 · 2021: $182 · 2022: $346 · 2024: $507 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $705.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $506.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $476.26 | 2019-2022 | |
| Lilly USA, LLC | $384.85 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $188.16 | 2019-2025 | |
| Exact Sciences Corporation | $183.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $182.93 | 2019-2025 | Repatha, Evenity, Otezla |
| E.R. Squibb & Sons, L.L.C. | $174.95 | 2019-2020 | |
| Viiv Healthcare Company | $174.84 | 2024-2025 | Apretude |
| Dexcom, INC. | $138.39 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.44 | 2019-2025 | Xifaxan |
| Abbvie INC. | $107.45 | 2019-2025 | |
| Abbott Laboratories | $92.60 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $80.30 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Inspire Medical Systems, INC. | $75.98 | 2024-2025 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $53.73 | 2024 | |
| Madrigal Pharmaceuticals | $43.35 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $43.08 | 2019 | |
| Allergan, INC. | $41.00 | 2019-2020 | |
| Sanofi Pasteur INC. | $36.61 | 2024-2025 | |
| Optinose US, INC. | $34.18 | 2024-2025 | |
| Eisai INC. | $33.97 | 2025 | |
| Corindus INC. | $26.25 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.37 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $24.75 | 2025 | Heplisav-B |
| Vertical Pharmaceuticals, LLC | $22.65 | 2019 | |
| Aimmune Therapeutics, INC. | $21.08 | 2025 | Zenpep |
| Edwards Lifesciences Corporation | $18.98 | 2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $17.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $17.03 | 2025 | Gemtesa |
| Amneal Pharmaceuticals LLC | $13.71 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.